Literature DB >> 11870884

Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.

Sophie North1, Olivier Pluquet, Daniela Maurici, Fatiha El-Ghissassi, Pierre Hainaut.   

Abstract

The aminothiol WR1065, the active metabolite of the cytoprotector amifostine, exerts its antimutagenic effects through free-radical scavenging and other unknown mechanisms. In an earlier report, we showed that WR1065 activates wild-type p53 in MCF-7 cells, leading to p53-dependent arrest in the G(1) phase of the cell cycle. To determine whether WR1065 activates p53 by modulating protein conformation, we analyzed its effects on p53 conformation and activity in the esophageal cancer cell line TE-1. This cell line contains a mutation in codon 272 of p53 (p53(V272M), with methionine instead of a valine), conferring temperature-sensitive properties to the p53 protein. At the nonpermissive temperature (37 degrees C), p53(V272M) adopts the mutant p53 conformation (nonreactive with the antibody PAb1620), does not bind specifically to DNA, and is not activated in response to DNA-damaging treatment. However, treatment with 0.5-4 mM WR1065 partially restored wild-type conformation at 37 degrees C, stimulated DNA binding activity, and increased the expression of p53 target genes WAF-1, GADD45, and MDM2, leading to cell-cycle arrest in G(1). These results suggest that WR1065 activates p53 through a mechanism distinct from DNA-damage signaling, which involves modulation of p53 protein conformation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870884     DOI: 10.1002/mc.10038

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  22 in total

1.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

2.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.

Authors:  Joel L Kaar; Nicolas Basse; Andreas C Joerger; Elaine Stephens; Trevor J Rutherford; Alan R Fersht
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

Review 4.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 5.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

6.  Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53.

Authors:  Nathalia Meireles da Costa; Agnès Hautefeuille; Marie-Pierre Cros; Matias Eliseo Melendez; Timothy Waters; Peter Swann; Pierre Hainaut; Luis Felipe Ribeiro Pinto
Journal:  Cell Cycle       Date:  2012-11-19       Impact factor: 4.534

Review 7.  Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Authors:  Alexander H Stegh
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

8.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

9.  Mutant p53 targeting by the low molecular weight compound STIMA-1.

Authors:  Nicole Zache; Jeremy M R Lambert; Nina Rökaeus; Jinfeng Shen; Pierre Hainaut; Jan Bergman; Klas G Wiman; Vladimir J N Bykov
Journal:  Mol Oncol       Date:  2008-03-07       Impact factor: 6.603

10.  Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

Authors:  Matteo Rossi; Jeong-Kyu Bang; Sharlyn Mazur; Jaclyn A Iera; Darren C Phillips; Gerard P Zambetti; Daniel H Appella
Journal:  Bioorg Med Chem Lett       Date:  2009-03-21       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.